<DOC>
	<DOCNO>NCT01068678</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , North America . The aim clinical trial compare efficacy safety NN1250 ( insulin degludec ( IDeg ) ) insulin glargine ( IGlar ) subject type 2 diabetes currently treat metformin alone metformin combined oral anti-diabetic drug ( OAD ) qualify intensified treatment .</brief_summary>
	<brief_title>Comparison NN1250 With Insulin Glargine Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Insulin na√Øve subject ( allow : previous short term insulin treatment 14 day ; Treatment hospitalisation gestational diabetes allow period longer 14 day ) Current treatment : metformin monotherapy metformin combination insulin secretagogues ( sulphonylurea ( SU ) glinide ) , DPP4 inhibitor , alphaglucosidaseinhibitor ( acarbose ) unchanged dose least three month prior Visit 1 minimum dos state : Metformin : alone combination ( include fix combination ) 1500 mg daily maximum tolerate dose ( least 1000 mg daily ) Insulin secretaguogue ( sulfonylurea glinide ) : minimum half daily maximal dose accord local labelling DPP4 inhibitor : minimum half daily maximal dose accord local labelling alphaglucosidaseinhibitor ( acarbose ) : minimum half daily maximal dose maximum tolerated dose HbA1c 7.010.0 % ( inclusive ) central laboratory analysis Body Mass Index ( BMI ) equal 45.0 kg/m^2 Use within last 3 month prior Visit 1 : thiazoledinediones , exenatide liraglutide Cardiovascular disease , within last 6 month prior Visit 1 , define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Uncontrolled treated/untreated severe hypertension ( systolic blood pressure least 180 millimetre ( mm ) mercury ( Hg ) and/or diastolic blood pressure least 100 mmHg ) Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement ( UK : adequate contraceptive measure define establish use oral , injected implant hormonal method contraception , sterilisation , intrauterine device intrauterine system , consistent use barrier method ) Cancer medical history cancer hereof ( except basal cell skin cancer squamous cell skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>